[NAVIGATOR trial (nateglinide)].
Tsujii
Satoru
S
Tenri Yorozu-sodansho Hospital Diabetes Center.
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003510:Cyclohexanes / Q000008:administration & dosage*; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000517:prevention & control*; D023381:Endpoint Determination; D018149:Glucose Intolerance / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D008019:Life Style; D000077715:Nateglinide; D010649:Phenylalanine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D011322:Primary Prevention; D016032:Randomized Controlled Trials as Topic; D012306:Risk
D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D007328:Insulin; D000077715:Nateglinide; D010649:Phenylalanine